Agar dilution MIC testing of amoxicillin, amoxicillin-BRL 42715, amoxicillin-clavulanate, temafloxacin, and clindamycin against 496 ,-lactamase-producing anaerobic gram-negative rods revealed MICs for 90o% of the strains tested of 256.0 (amoxicillin), 2.0 (amoxicillin-BRL 42715 and amoxicillin-clavulanate), and 4.0 (temafloxacin and clindamycin) ,ug/ml. Amoxicillin, temafloxacin, and clindamycin inhibited all 44 13-lactamase-negative strains (MICs for 90%o of the strains tested, <2.0 ,ug/ml). BRL 42715 will not be developed, but temafloxacin merits clinical evaluation.
identified (1, 12, 20) as described previously. P-Lactamase production was tested by the nitrocefin disk method (BBL Microbiology Systems, Cockeysville, Md.) (4) . MICs of amoxicillin, amoxicillin-clavulanate, amoxicillin-BRL 42715 (SmithKline Beecham Pharmaceuticals, Brockham Park, Betchworth, United Kingdom), temafloxacin (Abbott Laboratories, Chicago, Ill.), and clindamycin (The Upjohn Co., Kalamazoo, Mich.) were determined by agar dilution (2) as recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (18) . Inhibitors were tested at a fixed concentration of 2 ,ug/ml. Susceptibilities to amoxicillin (with or without inhibitors), clindamycin, and temafloxacin were evaluated at breakpoints of 2.0, 4.0, and 8.0 ,ug/ml, respectively (Table 1) . When available, NCCLS breakpoints were included in the analyses (18 extracts were standardized to contain similar units of activity against nitrocefin.
In Tables 1 and 2 , percent susceptibility rates of amoxicillin with and without inhibitors are presented at breakpoints of 2.0, 4.0, and 8.0 ,ugIml, respectively. Susceptibility data for ,B-lactamase-producing strains are shown in Table 1 . Against all 3-lactamase-positive strains, addition of BRL 42715 to amoxicillin lowered the MICs for 50 and 90% of the strains tested (MlC50 and MIC90, respectively) from 32 and 256 to 0.25 and 2 ,ug/ml, respectively, and 99% of the strains were susceptible at all three amoxicillin breakpoints (27% of the strains were susceptible to amoxicillin at the NCCLS breakpoint of 4 ,ug/ml). Addition of clavulanate to amoxicillin lowered the MIC50 and MIC90 to 0.5 and 2.0 ,ug/ml, respectively, with 97% of the strains susceptible at the NCCLS amoxicillin breakpoint of 8 ,ug/ml (18) . Temafloxacin and clindamycin showed good activity against 13-lactamase-producing strains (95 and 98%, respectively, were susceptible at .4 ,ug/ml), but clustering near the breakpoint was seen with both compounds.
All ,B-lactamase-negative strains were susceptible to amoxicillin, temafloxacin, and clindamycin (Table 2) , and many were susceptible to the inhibitors alone (MICs, <8
[tgIml). Of note were the significantly lower MIC50s and MIC90s of both temafloxacin and clindamycin against ,B-lactamase-negative strains (0.25 and 2.0 ,ug/ml and .0.125 and 0.5 ,ug/ml, respectively) than against ,-lactamase-positive strains (Table 2) .
Of (18) .
The current study shows that BRL 42715, in addition to reported activity against many ,-lactamases from aerobes, is also active against ,B-lactamases of anaerobes. Clindamycin was active against 98% of the strains tested. Because of generalized hospital use of this compound in the United States, clindamycin resistance may occur (22) and should be monitored for. Temafloxacin was active against 95% of all strains at c4 ,ug/ml, but MICs clustered around the breakpoint. However, with a mean peak level in serum of 7.1 ,ug/ml and a mean trough level in serum of 3.4 ,ug/ml (10, 19) , results point to possible clinical efficacy. Temafloxacin MICs were similar to those described previously (11, 16) , i.e., lower than those for ciprofloxacin and ofloxacin (16, 21) and comparable to those for tosufloxacin (6) and sparfloxacin (21) .
MICs of clindamycin and temafloxacin against P-lactamase-negative anaerobic gram-negative bacilli were lower than those against 3-lactamase-positive strains. This phenomenon has been reported for tosufloxacin, tetracycline, and trospectomycin and may reflect a generalized permeability barrier in ,-lactamase-producing strains (6, 15) .
In summary, BRL 42715 showed potent inhibitory activity against P-lactamases from anaerobic gram-negative bacilli.
Unfortunately, the compound is not being developed. 
